TCTMD

Medtronic Resolute® Drug-Eluting Stent Exhibits Strong Safety Profile in Broad Spectrum of Patients

Late-breaker at EuroPCR Confirms Low Rates of Adverse Events with Novel Heart Device in More Than 5,000 Study Subjects PARIS – A pooled analysis of the global RESOLUTE clinical program presented today ...
Yahoo Finance

Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy

Medtronic plc MDT announced the receipt of the CE Mark for its one-month dual antiplatelet therapy (DAPT) indication to address high bleeding risk (HBR) patients who are implanted with the Resolute ...
TCTMD

Medtronic Resolute® Drug-Eluting Stent Shows Superiority to Taxus® DES in Study of Patients with Coronary Artery Disease

MINNEAPOLIS, MN - The Resolute® drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.’s Taxus® DES on the primary endpoint of the RESOLUTE Japan clinical study: ...
Nasdaq

Medtronic Resolute Onyx™ Drug Eluting Stent (DES) First to Receive One-Month DAPT Labeling in the U.S. with Expanded Indication for High Bleeding Risk Patients

DUBLIN, Oct. 1, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new ...
Forbes

FDA Approves Medtronic's Resolute Drug-Eluting Stent for Treatment of CAD, Including Diabetics

The FDA has approved the Medtronic Resolute zotarolimus-eluting stent for the treatment of coronary artery disease. The Resolute DES is approved for use in a wide variety of patients, including ...
Nasdaq

Medtronic Resolute Onyx™ DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe

DUBLIN, June 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual ...
News Medical

FDA approves Medtronic's Resolute Integrity DES to treat CAD

Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity ...
Business Wire

Medtronic Resolute Integrity Drug-Eluting Stent Obtains FDA Approval for Treating Coronary Artery Disease

Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide MINNEAPOLIS--(BUSINESS WIRE)--Advancing the clinical practice of ...
News Medical

Medtronic Resolute DES found effective through two years

According to new clinical data presented today at ACC.12 -- the 61 st Annual Scientific Session & Expo of the American College of Cardiology (ACC) -- the Resolute drug-eluting stent (DES) from ...
Fierce Healthcare

Medtronic Resolute® Drug-Eluting Stent Offers Strong Performance in Diabetic Patients with Heart Disease

Clinical Data from Multiple Studies Presented at EuroPCR Show Next-Generation Device Delivers Excellent Safety and Efficacy in Challenging Patient Population PARIS--(BUSINESS WIRE)-- For patients with ...
FierceBiotech

MEDTRONIC RESOLUTE INTEGRITY™ DRUG-ELUTING STENT OBTAINS FDA APPROVAL FOR TREATING CORONARY ARTERY DISEASE

MINNEAPOLIS –– Advancing the clinical practice of interventional cardiovascular medicine, Medtronic Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute ...